Xencor (XNCR) Tops Q4 EPS by $1.31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Xencor (XNCR) Tops Q4 EPS by $1.31

Xencor Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022 4:01 PM EST

-- Management to Host Conference Call at 4:30 p.m. ET Today --

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a review of recent business and clinical highlights.

In 2021, we made significant decisions to advance our portfolio of internal XmAb® drug candidates the initiation of Phase 2 trials in prostate cancer with vudalimab, the entry into our second... More